Welcome to our dedicated page for Titan Pharmaceut news (Ticker: TTNP), a resource for investors and traders seeking the latest updates and insights on Titan Pharmaceut stock.
Titan Pharmaceuticals, Inc. (formerly Nasdaq: TTNP) has generated a series of material news events that trace its evolution from a development stage biopharmaceutical company centered on the ProNeura long-term, continuous drug delivery technology to a wholly owned subsidiary within a new holding company structure. News coverage for TTNP spans technology development, asset sales, capital raising, corporate governance, listing status, and a transformative reverse merger.
Earlier news releases describe Titan as a development stage company developing proprietary therapeutics using ProNeura, with potential applications in chronic conditions where consistent, around-the-clock blood levels of medication may benefit patients. Subsequent announcements highlight a significant asset sale to Fedson, Inc., in which Titan agreed to sell certain ProNeura assets, including its portfolio of drug addiction products (Probuphine and Nalmefene implant programs) and other early development programs based on the ProNeura platform, in exchange for upfront consideration, potential milestone payments, and royalties.
Investors following TTNP-related news will also find detailed reports on multiple private placements of convertible preferred stock, including Series AA preferred stock sold to The Sire Group Ltd. and Series B and Series C preferred stock issued to Blue Harbour Asset Management L.L.C-FZ. These transactions, described in press releases and 8-K filings, include conversion features and ownership limitations linked to Nasdaq listing rules, and are accompanied by registration rights agreements.
Corporate and listing developments form another key stream of Titan news. The company announced a 1-for-20 reverse stock split of its common stock, later reported that it had regained compliance with Nasdaq’s minimum bid price requirement, and then disclosed Nasdaq notices related to periodic reporting and audit committee composition. The most consequential news items concern Titan’s Merger and Contribution and Share Exchange Agreement with TalenTec Sdn. Bhd. (formerly KE Sdn. Bhd.) through Black Titan Corporation, and the subsequent completion of this reverse merger, after which TTNP common stock was expected to cease trading on the Nasdaq Capital Market.
For readers researching TTNP, this news archive provides a chronological view of Titan’s strategic alternatives process, key financing decisions, asset divestitures, board changes, and the final steps leading to its combination with TalenTec and the transition of its public listing to Black Titan ordinary shares. Regular review of these historical news items helps contextualize the company’s path and the regulatory filings associated with its corporate transformation.
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) announced a debt settlement with Molteni & C. dei F.lli Alitti and Horizon Credit LLC II, resolving approximately $5.2 million in debt for $1.6 million in cash and asset transfers. This settlement is a significant step towards the company's restructuring, eliminating liens on remaining assets. Titan is winding down U.S. commercial activities for its Probuphine product, with expectations to complete this process soon. The agreement's closing is contingent on customary conditions and financing completion.
Titan Pharmaceuticals (NASDAQ:TTNP) announced a strategic restructuring on October 15, 2020, focusing on ProNeura-based product development. Key changes include discontinuing U.S. sales of Probuphine, reducing operating costs, and negotiating debt elimination. The company aims to enhance its R&D capabilities, particularly with a kappa opioid receptor agonist and a nalmefene implant. Despite having a grant of $8.7 million for nalmefene development, challenges persist in commercializing Probuphine due to financial constraints and low market demand, exacerbated by the COVID-19 pandemic.
Titan Pharmaceuticals (NASDAQ: TTNP) announced a registered direct offering of 19,440,000 shares at $0.14 per share, raising approximately $2.5 million after expenses. The offering is set to close around September 28, 2020. Maxim Group LLC acts as the sole placement agent. This transaction allows Titan to bolster finances for ongoing operations and product developments, including its lead product, Probuphine, a treatment for opioid use disorder. The offering is conducted under a shelf registration statement effective since April 24, 2019.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced that stockholders have approved an amendment to increase the number of authorized shares of common stock from 125 million to 225 million. This decision was made during a special meeting held on September 18, 2020. The results of the voting are documented in a Current Report on Form 8-K filed with the SEC. Titan's Executive Chairman, Dr. Marc Rubin, expressed gratitude for stockholders' support and anticipated progress updates. Titan is known for its ProNeura technology and the Probuphine implant for opioid dependence, approved by the FDA in May 2016.
Titan Pharmaceuticals (NASDAQ: TTNP) announced an exclusive distribution agreement between its partner Molteni Farmaceutici and Accord Healthcare Europe for the commercialization of Sixmo® (buprenorphine implant) in the EU. This partnership combines Molteni's expertise in opioid addiction treatments with Accord's market reach. Titan expects to receive approximately $1.1 million from milestone and royalty payments starting in the second half of 2021, reinforcing the product's potential in addressing the opioid crisis.
Titan Pharmaceuticals (NASDAQ: TTNP) provided an update regarding its upcoming special stockholder meeting aimed at obtaining approval for increasing the number of authorized shares. Without this approval, Titan's management anticipates that its operations could cease, leading to a total loss of shareholder value due to asset pledges against outstanding debt. As of September 11, 2020, about 30.7 million shares had not been voted, with roughly 72% of votes favoring the amendment. The Board urges stockholders to vote as only a small fraction of additional affirmative votes are needed to proceed.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) reported second-quarter financial results on August 14, 2020, with revenues of approximately $1.3 million, up from $0.5 million in Q2 2019. The increase was driven by a $1.2 million NIDA grant, although product sales declined due to COVID-19 related restrictions. Operating expenses rose to about $5.7 million. The net loss was approximately $4.6 million or $0.05 per share, an improvement from $5.2 million or $0.38 per share in the same quarter last year. The company has $5.5 million in cash, which it believes will fund operations through Q3 2020.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) will release its second quarter 2020 financial results on August 14, 2020. A conference call is scheduled for the same day at 9:00 a.m. PT to discuss the results and provide a business review. The call will feature executives including Sunil Bhonsle, President and CEO. Titan's leading product, Probuphine®, offers a long-acting solution for opioid dependence and was FDA-approved in May 2016. The ProNeura® technology is expected to play a role in future chronic condition treatments.